

## Review: Emerging Nucleic Acid–Based Tests for Point-of-Care Detection of Malaria

Michael S. Cordray\* and Rebecca R. Richards-Kortum  
*Department of Bioengineering, Rice University, Houston, Texas*

**Abstract.** Malaria remains a serious disease in the developing world. There is a growing consensus that new diagnostics are needed in low-resource settings. The ideal malaria diagnostic should be able to speciate; measure parasitemia; low-cost, quick, and simple to use; and capable of detecting low-level infections. A promising development are nucleic acid tests (NATs) for the diagnosis of malaria, which are well suited for point-of-care use because of their ability to detect low-level infections and speciate, and because they have high sensitivity and specificity. The greatest barrier to NAT use in the past has been its relatively high cost, and the amount of infrastructure required in the form of equipment, stable power, and reagent storage. This review describes recent developments to decrease the cost and run time, and increase the ease of use of NAT while maintaining their high sensitivity and specificity and low limit of detection at the point-of-care.

### INTRODUCTION

Malaria is one of the most serious of the diseases of poverty and is widespread across the developing world causing 200–500 million illnesses, and more than 1 million deaths each year.<sup>1–3</sup> Malaria accounts for up to 20% of all childhood deaths in Africa.<sup>4–6</sup> In many of the areas to which malaria is endemic, there is a lack of access to effective diagnostics, leading to poor surveillance of malaria infections and treatment, poor health outcomes for non-malarial fever patients, and a public lack of trust in the health system.<sup>7</sup> In addition, over-prescription of cheap antimalarial drugs has led to development of widespread drug resistance, and drugs that remain effective, such as artemisinin-derived treatments, are much more expensive (approximately \$1–\$2 per day), leading to an increased need for accurate diagnosis before treatment.<sup>8–12</sup> Thus, there is a growing consensus that there is a need for new diagnostics that are more accessible in malaria-endemic areas, and that have improved performance over existing techniques to help guide the distribution of antimalarial drugs, to more effectively target the disease, and to reduce the generation of drug-resistant strains.<sup>13</sup>

A major limitation of malaria diagnosis is that most cases occur in areas with limited health care infrastructure.<sup>3,14–16</sup> To be useful in these circumstances, a diagnostic should be low cost, require minimal or no external power, be able to be run on portable and easy to maintain equipment, be usable without extensive training, not require refrigerated reagent storage and deliver accurate and unambiguous results rapidly. The World Health Organization has established a set of principles to guide the development of diagnostics for these low-resource, point-of-care (POC) settings known as ASSURED. A test should be Affordable, Sensitive, Specific, User-friendly, Rapid and Robust, Equipment-free, and Deliverable to end-users.<sup>17</sup> In addition, the ideal malaria diagnostic should be able to determine which species is infecting the patient, determine the level of infection (measured as parasitemia, the percentage of infected erythrocytes), and be capable of detecting low level infections.

Nucleic acid tests (NATs) have been suggested as a way to meet these criteria, and a number of NATs are being devel-

oped to detect malaria in POC settings. Currently, NATs for malaria are used primarily in central health facilities because they tend to be more resource intensive. The focus of this review is on the development of NATs that can be implemented in POC settings. For the foreseeable future, many of these NATs will be most practical in laboratory settings in these low-resource countries, but there is increased focus on adapting NATs into systems that might be directly used at the POC. In this article, we review current malaria diagnostics and discuss their benefits and drawbacks. We then examine emerging malaria NATs for POC settings, comparing their diagnostic performance and their potential utility in low-resource settings.

### CURRENT MALARIA DIAGNOSIS

**Blood film microscopy.** The most commonly used laboratory diagnostic method for malaria is Giemsa-stained blood microscopy.<sup>18,19</sup> A blood smear sample can be read by a skilled technician in 20 minutes and costs approximately \$0.20 per sample, including the cost of staining reagents and the technician's time. Two different staining techniques, the thin and thick blood smear, are used for malaria diagnosis. The thin blood smear more accurately preserves malaria parasite morphology and enables easier speciation of the infecting parasite. A thick blood smear is used to quickly observe a larger volume of blood more quickly, which increases the sensitivity of the diagnosis by approximately 10-fold; however, it is more difficult to speciate the infection because of distortions in morphology.<sup>20</sup> A highly trained technician using these techniques can reliably detect as few as 50 parasites/ $\mu$ L of blood, with a sensitivity and specificity of 95% and 98% (using the polymerase chain reaction [PCR] as a gold standard).<sup>21</sup>

There is a growing consensus that blood smear microscopy is inadequate as a malaria diagnostic. The quality of blood smear examination is highly dependent on the quality of the microscope, the quality of the available staining reagents, and the skill of the technician.<sup>22,23</sup> A study comparing the performance of thick and thin blood smear microscopy in expert laboratory and field conditions tested 3,004 blood smears and found that the sensitivity decreased to 10% when samples were examined in rural villages in Thailand compared with the same samples reexamined in a laboratory.<sup>23</sup> This change was attributed mainly to the difficulty less-trained technicians had recognizing low-level infections, and

\*Address correspondence to Michael S. Cordray, Department of Bioengineering, Rice University, 6500 Main Street, MS-142, Houston, TX 77030. E-mail: mikec@rice.edu

other research has found that microscopy may miss as many as 50% of the cases detected by PCR.<sup>23,24</sup>

**Antigen detection and rapid diagnostic tests.** A recent advance in malaria diagnosis has been the commercialization of lateral flow immunoassay rapid diagnostic tests (RDTs). These tests are easy to use because the user only needs to spot the patient's blood onto the base of the strip and wait for the result (approximately 20 minutes).<sup>25,26</sup> The RDTs have a cost between \$0.45 and \$1.40 per test to the end user, and an average cost of approximately \$0.85.<sup>12</sup> Approximately 20% of the final cost of RDTs to the user represent shipping and local storage and transportation costs.<sup>27</sup> The RDTs have a reported detection limit of > 100 parasites/ $\mu$ L and 80–95% sensitivity and 85% specificity using microscopy as a gold standard.<sup>12,26,28–34</sup>

The World Health Organization recently launched a large review of the performance of commercially available malaria RDTs and found wide variation between tests from different manufacturers and between different lots of the same diagnostic. Variation was found to be especially high when parasitemia was less than 200 parasites/ $\mu$ L of blood.<sup>35–37</sup> Recent studies have shown that there is greater variation than believed in the incidence and structure of the *Plasmodium falciparum* histidine-rich protein, which is the target of many RDTs, and might account for some of this variability.<sup>38–40</sup> In addition, RDTs become degraded and less sensitive and specific at temperatures commonly found in POC clinics.<sup>41</sup> Careful management of RDT procurement, transportation, and storage can prevent RDT degradation and they can be an effective tool in malaria diagnosis, but good management of RDTs increases the cost and difficulty of using them in POC environments.<sup>42</sup> The RDTs can also show false-positive results because of antigens circulating for up to two weeks after the infection has ended.<sup>43</sup> Malaria RDTs also do not currently offer the ability to test for the markers of drug resistance or to quantify the level of infection.<sup>44</sup>

**Polymerase chain reaction.** The NATs offer advantages because they can speciate infections and test for drug resistance.<sup>43,45–49</sup> Most NATs for malaria focus on the 18S ribosomal RNA gene, which contains regions conserved across all *Plasmodium* species and regions specific to each species.<sup>46,47,50</sup> Depending on the technology used, tests may target either the 18S gene directly or its associated mRNA. DNA targets offer the advantage of being more stable, enabling long-term storage of patient samples before testing. DNA circulating post-infection may lead to false-positive diagnostic results.<sup>51</sup> The advantage of using RNA as a target for diagnostics is that it is much more abundant in the cell

than DNA, with up to 1,000 rRNA copies of the 18S gene per parasite.<sup>52</sup>

The PCR is more sensitive than either RDTs or microscopy, and has been found to be especially effective at identifying low-level infections often missed by other techniques, and has a limit of detection of 0.5–5 parasites/ $\mu$ L.<sup>53–57</sup> However, PCR-based assays are the least feasible to perform at the POC. The PCR is prone to contamination, the nucleic acids must be extracted and purified from the patient sample, and reagents must be stored cold to maintain their function. The reagents for PCR diagnostics can cost approximately \$1.50–\$4 per test.<sup>58–61</sup> A summary of the performance of current malaria diagnostics is shown in Table 1. There is a growing consensus that there is a need for new malaria diagnostic tools to overcome their limitations, especially in POC settings.<sup>3,62,63</sup>

## EMERGING NUCLEIC ACID TESTS

The NATs have the potential to offer many advantages at the POC, such as low limits of detection, the ability to speciate, and to quantify the level of infection. For malaria diagnosis, many NATs consist of a separate amplification and detection step because there is insufficient *Plasmodium* nucleic acid in a peripheral blood sample for direct detection by using current detection technologies.<sup>47</sup> Emerging NATs for malaria diagnosis seek to be appropriate for the POC through a variety of methods, including reducing the cost and difficulty of the amplification step and generating a quick and easy to use detection schemes. The diagnostic performance of the POC NATs discussed below is summarized in Table 2.

**Isothermal amplification.** Isothermal amplification techniques operate at a single temperature, eliminating the need for a thermocycler, enabling them to be conducted on simple and portable heating systems. Several isothermal amplification techniques have been developed in recent years, such as helicase-dependent amplification, rolling circle amplification, and nicking enzyme amplification reaction.<sup>64–66</sup> Of the various isothermal amplification techniques, two in particular, loop-mediated isothermal amplification (LAMP) and nucleic acid sequence-based amplification (NASBA), have been extensively explored for malaria diagnosis.

**Loop-mediated isothermal amplification.** The most extensively studied amplification technique for the detection of malaria is LAMP. This procedure uses a complex set of four primers that after initial binding and amplification steps form a stem-and-loop structure, which leaves a binding site constantly open for new primers to anneal. The LAMP is a highly

TABLE 1

Summary of diagnostic performance of established malaria diagnostics\*

Assay	Reference	<i>Plasmodium</i> species detected	Limit of detection	Sensitivity (gold standard)	Specificity (gold standard)
Laboratory-based thin blood smear microscopy	19	<i>falciparum</i> , <i>vivax</i> , <i>malariae</i> , <i>ovale</i>	50 parasites/ $\mu$ L	95.7% (consensus of microscopy and PCR)	97.9% (consensus of microscopy and PCR)
Field-based thin blood smear microscopy	21	<i>falciparum</i> , <i>vivax</i> , <i>malariae</i> , <i>ovale</i>	50 parasites/ $\mu$ L	10% (laboratory microscopy)	99.3% (laboratory microscopy)
RDTs tested in malaria-endemic countries	31	<i>falciparum</i> , <i>vivax</i>	> 100 parasites/ $\mu$ L	80–95% (microscopy)	85% (microscopy)
Laboratory PCR	43	<i>falciparum</i> , <i>vivax</i> , <i>malariae</i> , <i>ovale</i>	0.5–5 parasites/ $\mu$ L	100%†	100%†

\* RDTs = rapid diagnostic tests.

† Laboratory polymerase chain reaction (PCR) is generally considered the most sensitive of the established diagnostics for malaria and is used as the gold standard when comparing it to other malaria diagnostic techniques.

TABLE 2  
Summary of diagnostic performance of potential point-of-care appropriate nucleic acid tests\*

Assay	Reference	<i>Plasmodium</i> species detected	Limit of detection	Sensitivity (gold standard)	Specificity (gold standard)
LightCycler PCR	65	<i>falciparum</i> , <i>vivax</i> , <i>malariae</i> , <i>ovale</i>	10 parasites/ $\mu$ L	97% (microscopy)	100% (microscopy)
RT-PCR	67	<i>falciparum</i> , <i>vivax</i> , <i>malariae</i> , <i>ovale</i>	< 0.1 parasites/ $\mu$ L	100% (microscopy)	93% (microscopy)
PCR LDA	66	<i>falciparum</i> , <i>vivax</i> , <i>malariae</i> , <i>ovale</i>	1 parasite/ $\mu$ L	100% (PCR)	90% (PCR)
PCR ELISA	70	<i>falciparum</i> , <i>vivax</i> , <i>malariae</i> , <i>ovale</i>	0.3–10 parasites/ $\mu$ L < 30 parasites/ $\mu$ L	91.4% (microscopy)	95.8% (microscopy)
LAMP	57	Pan, <i>falciparum</i> , <i>vivax</i> , <i>malariae</i> , <i>ovale</i>	0.2 parasites/ $\mu$ L ( <i>malariae</i> , <i>ovale</i> ), 2 parasites/ $\mu$ L (Pan, <i>falciparum</i> , <i>vivax</i> )	98.5% (microscopy)	94.3% (microscopy)
	56	<i>falciparum</i>	$\geq$ 0.2 parasites/ $\mu$ L	95% (PCR)	99% (PCR)
	58	<i>falciparum</i>		76.1% (PCR)	89.6% (PCR)
	60	Pan, <i>falciparum</i>	5 parasites / $\mu$ L	93.3% (PCR)	100% (PCR)
NASBA	38	<i>falciparum</i>	0.02 parasites/ $\mu$ L	100% (microscopy)	86% (microscopy)
	62	<i>falciparum</i> , <i>vivax</i> , <i>malariae</i> , <i>ovale</i>	0.01–0.1 parasites/ $\mu$ L		
NALFIA	71	Pan	0.3–3 parasites/ $\mu$ L	98% (PCR)	99% (PCR)

\*PCR = polymerase chain reaction; RT = reverse transcription; LDA = lactate dehydrogenase assay; ELISA = enzyme-linked immunosorbent assay; LAMP = loop-mediated isothermal amplification; NASBA = nucleic acid sequence-based amplification; NALFIA = nucleic acid lateral flow immunoassay.

efficient technique capable of achieving  $10^8$  fold amplification in as little as one hour.<sup>67</sup> It also generates a magnesium pyrophosphate precipitate during amplification, which can be used for detection by measuring the turbidity of the solution.<sup>68,69</sup>

Loop-mediated isothermal amplification was first used for diagnosis of malaria in 2006 for  $n = 202$  patient samples obtained in Thailand. An easy to implement sample preparation method was also investigated during this study, which was boiling blood samples of the patients for 10 minutes to release the parasite DNA. The amplified malaria DNA was monitored by using a real-time turbidity measurement to track generation of a precipitate. This study used microscopy as a gold standard and determined that LAMP had a sensitivity of 95% and a specificity of 99%. Investigators detected 10 copies of target serially diluted from a clinical specimen in a 50  $\mu$ L sample, suggesting a detection limit of 0.2 parasites/ $\mu$ L of blood.<sup>70</sup>

The LAMP primer sets have been designed for each of the four species of malaria, as well as a pan-*Plasmodium* set. These LAMP primers were tested on 121 patient samples obtained in rural Thailand. DNA preparation was accomplished by boiling the blood samples for 10 minutes. The pan-specific reactions provided results in approximately 25 minutes, and each of the species-specific amplifications provided results in approximately 35 minutes. The limit of detection was determined by using positive control plasmids; for *P. malariae* and *P. ovale*, this limit of detection was 0.2 parasites/ $\mu$ L of patient blood, and the limit of detection for remaining primer sets was 2 parasites/ $\mu$ L of blood. Using microscopy as a gold standard, the investigators found that on average for each of the primer sets, the sensitivity was 98.5% and the specificity was 94.3%.<sup>71</sup>

The performance of LAMP using turbidity for detection and boiling for DNA extraction was compared with gel electrophoresis and a commercial DNA extraction kit on samples from Bangladesh ( $n = 115$ ). Investigators found that LAMP using commercial DNA extraction and gel electrophoresis had a sensitivity of 76.1% and a specificity of 89.6% (laboratory PCR was used as a gold standard). Although boiling alone did not affect the performance of the assay compared with that of the commercial kit, using boiling and turbidity as

a detection method together decreased the specificity to 58.3%. This decrease in specificity was attributed to the non-specific nature of visual detection, and the increase in non-targeted DNA from the sample preparation technique. The investigators in this study concluded that further optimization of LAMP to reduce non-specific amplification is necessary before heating can be used as a POC sample preparation technique, but that overall LAMP remains a promising technique for malaria diagnosis. The reagent cost of LAMP was \$0.40–\$0.70 per test, which was comparable to the price to the consumer of an RDT strip.<sup>72</sup> However, extra LAMP reactions would need to be run as positive controls, which are included in the price of a single RDT, increasing the cost of LAMP. This cost is also increased by the additional resources required to implement it.

A heating system has been developed for LAMP that does not require an external power source. The system uses an exothermic reaction, CaO and water, and the heat from this reaction is coupled with a phase-change material with a melting temperature of 62°C. A prototype was built that maintained the LAMP amplification temperature (62–65°C) for 45 minutes from a single CaO reaction. When turbidity was used as a detection method, LAMP could be conducted with samples spiked with *P. falciparum* DNA without requiring an external power source, maintaining the same limit of detection as LAMP conducted with a conventional laboratory heat source.<sup>73</sup>

The LAMP is a promising method for the POC diagnosis of malaria. It has a low limit of detection (0.2–2 parasites/ $\mu$ L), a high sensitivity and specificity, ranging from sensitivity = 76.1–98.5% and specificity = 89.6–100%, produces a result in 30 minutes to 2 hours, and enables visual readout of results.<sup>70–72,74</sup> One major drawback of LAMP is that it is prone to contamination and amplification of non-targeted DNA sequences, which decreases the specificity of the assay.<sup>71,74</sup> There is a potential to increase the field specificity of LAMP by coupling it with a targeted detection system.<sup>72</sup>

*Nucleic acid sequence-based amplification.* Nucleic acid sequence-based amplification is a different isothermal amplification method that has recently been applied to malaria diagnosis. The NASBA reaction continually cycles between



the activity of a reverse transcriptase to copy an RNA sequence into a cDNA, and the activity of a T7 RNA polymerase for subsequent amplification. It generates a high number of RNA copies per cycle, enabling it to generate detectable product in a shorter time frame than other amplification techniques.<sup>75</sup>

The NASBA RNA probes were designed for the *P. falciparum* and *P. vivax* 18S mRNA and tested on 99 samples.<sup>76</sup> The samples were amplified for one hour by using a commercial thermal cycler, which was used to monitor the progress of the NASBA reaction in real time. The limit of detection of the assay was determined by using serial dilutions of clinical samples and was 0.1–0.01 parasites/ $\mu$ L of blood, and NASBA was found to be quantitative.<sup>76</sup>

The NASBA was further tested on samples from areas of high (rural Kenya,  $n = 149$ ) and low (urban Tanzania,  $n = 154$ ) malaria prevalence. The NASBA reaction was conducted in an real time PCR system alongside laboratory PCR with microscopy as a gold standard. In the sample set from Kenya, the correlation between NASBA and microscopy was 0.80, and PCR and microscopy had a correlation of 0.76. In the lower incidence population of Tanzania, the correlation of NASBA with microscopy decreased to 0.33, and the correlation of PCR with microscopy decreased to 0.25.<sup>45</sup> Because PCR and NASBA are more sensitive to low-level infections, the decrease in correlation is caused by infections missed by microscopy, further suggesting that PCR and NASBA are especially useful in low prevalence areas where low-level infections are more common.<sup>45,77</sup>

The NASBA has a high degree of specificity and sensitivity, can produce results in an hour, has the lowest limit of detection of any of the investigated malaria diagnostics, and has a detection limit of 0.01 parasites/ $\mu$ L of blood as determined by serial dilution of clinical samples of known parasitemia. Some of the limitations of NASBA as a POC technique are that it is prone to contamination and false-positive results, and that it requires more extensive sample preparation than LAMP. The cost of NASBA reagents is approximately \$5–\$20 per test, making it expensive for malaria diagnosis.<sup>78</sup> However, because it is the most sensitive to low-level infections, NASBA has the potential to be especially useful as a screening tool despite a relatively high cost.

Isothermal amplification techniques such as NASBA and LAMP are promising for malaria diagnosis in POC settings. They eliminate the need for a costly and power-intensive thermocycler; produce results in a short time, from 30 minutes (LAMP) to 1 hour (NASBA); and are capable of detecting infections of  $< 1$  parasite/ $\mu$ L of blood. The sensitivity and specificity of these techniques are comparable to those of PCR-based diagnostics, although the specificity of LAMP decreases because of non-targeted amplification. The LAMP can also be used with samples that have undergone minimal pre-processing, and results can be monitored with turbidity measurements, making it especially suited for use as a malaria POC diagnostic because it has comparable material costs to the commercial price to users of RDTs.<sup>72</sup> However, extra amplifications would be needed to be run to compensate for the fact that amplifications do not include a built-in positive control as in commercial RDTs. Although it is the most sensitive to low level infections, NASBA is currently too expensive for practical POC use, making it more appropriate for use in regional or central health facilities. One of the major draw-

backs of isothermal amplification techniques is that so far they have been tested only in relatively well equipped laboratories.

**Novel PCR-based detection methods.** Although traditional PCR is an extremely sensitive (97%) and specific (100%) technique compared with microscopy, with the ability to amplify low levels of infection, it is limited at the POC by a susceptibility to contamination, expensive reagents, and the need for a stable power supply and thermocycler.<sup>79–81</sup> There is a growing interest in developing novel processing and detection techniques to adapt laboratory PCR into a POC tool.

Several NATs for malaria at the POC focus on finding ways to couple PCR with novel detection systems. Novel detection strategies can be used to increase the utility of an amplification reaction by speciating malaria in a single reaction (one-pot detection), by reducing the amount of required amplification, or by removing the need for special detection systems.<sup>68,69,80,82,83</sup> Some of these detection techniques may eventually be coupled with isothermal amplification techniques to combine the benefits of POC amplification and detection.

A commercial wellplate enzyme-linked immunosorbent assay (ELISA) has been adapted into a NAT for detection of malaria by using capture oligonucleotides instead of antibodies. Traditional PCR amplification biotinylated primers and a horseradish peroxidase–conjugated streptavidin are used with a chromogenic horseradish peroxidase substrate for detection. This technique was tested in the field on 300 patients in Thailand, where researchers were able to achieve a sensitivity of 91.4% and a specificity of 95.8% (using microscopy as a gold standard) and a detection limit of 30 parasites/ $\mu$ L, determined by the lowest microscopic parasitemia detected by the PCR-ELISA.<sup>84</sup> The PCR-ELISA enables high throughput screening, is able to detect mixed infections, and has successfully been tested in a low-resource setting. However, the major drawback is that it requires the infrastructure to support PCR and a wellplate reader.

A major focus of research into adapting PCR for the POC is the development of single-pot detection systems that enable identification of more than one infecting species of malaria from a single amplification reaction. In the PCR ligase detection reaction (PCR LDR), DNA probes for each *Plasmodium* species are designed of different lengths to be resolved separately by electrophoresis on a gel.<sup>80</sup> When tested with 189 samples from Papua New Guinea, the PCR LDR had a limit of detection using diluted cultured parasites of 1 parasite/ $\mu$ L, a sensitivity of 100%, and a specificity of 90%, using expert microscopy as a gold standard.<sup>80</sup> Although this technique was able to detect each species of malaria from a single amplification, it is unsuited for POC use because it can take hours to resolve the different bands, requires a stable power supply to run the gel, and requires a secondary detection step to locate the DNA in the gel.

The PCR LDR was improved by introducing a fluorescent microsphere assay for detection (LDR-FMA). Commercial microspheres tagged with a specific sequence (Luminex FlexMap probes) are used for detection. Different FlexMap microspheres, uniquely labeled with specific fluorophores, recognize species-specific DNA sequences and are used to quantify the presence of individual *Plasmodium* species.<sup>82</sup>

The LDR-FMA was tested on cultured malaria samples and had a concordance  $> 90\%$  with microscopy and a limit of detection of 20 parasites/ $\mu$ L of blood, which was determined on the basis of the lowest parasitemia measured by

microscopy that was positive by LDR-FMA. The detection step was estimated to cost \$0.30 per patient; however, this cost does not include the cost of the necessary amplification step.<sup>82</sup> The drawback to this technique is that it is relatively time-consuming and requires a sophisticated BioPlex Array reader capable of measuring the difference between different fluorescent tags used.

Another approach to developing a fluorescent one-pot detection system for malaria used a series of fluorescence resonance energy transfer–based DNA probes and the commercial LightCycler system. Probes are designed to bind to a species-specific region of the 18S ribosomal DNA and each different probe was designed so that it had a unique melting temperature. By using a carefully controlled temperature source (an RT-PCR machine), it was possible to differentiate between different probes by measuring their melting temperatures. This method was tested on 297 samples from Thailand and enabled highly sensitive differentiation and separate quantitation of mixed parasite infections in a single reaction.<sup>79</sup> When this technique used microscopy as the gold standard, it had a sensitivity of 97% and a specificity of 100%. The limit of detection was determined by using a positive control plasmid spiked into uninfected blood samples and was 1 parasite/ $\mu$ L. The major drawback of this technique as a POC tool is that it requires sophisticated temperature control and fluorescence detection systems.

The nucleic acid lateral flow immunoassay (NALFIA) is an attempt to create a rapid, easy-to-use detection method for DNA targets that is entirely self-contained. The NALFIA is

intended to be coupled with an isothermal amplification method, although so far it has only been tested with laboratory PCR. The NALFIA is analogous to the lateral flow immunoassay technology used in RDTs, but uses DNA capture and recognition sequences and antibodies to attach these sequences to the reporter molecule and the nitrocellulose. As with RDTs, the reagents can be pre-set on the nitrocellulose strip so that a user only needs to apply a sample and wait for a result to develop (approximately 10 minutes).<sup>85</sup>

The NALFIA was tested under field conditions in Mbita, Kenya on 650 patient samples. Samples were purified by using commercial kits and amplified with PCR before being spotted on NALFIA strips. This technique had a sensitivity of 98% and a specificity of 99% (PCR as a gold standard). The limit of detection was measured by using serial dilutions of a *Plasmodium* culture and was 0.3–3 parasites/ $\mu$ L. The NALFIA is one of the best suited NATs for use in POC settings because it is extremely fast, has high sensitivity and specificity, is simple to use, and the result is determined through visual detection. Some of the drawbacks of NALFIA are that it requires a separate amplification step, and that it includes antibodies similar to those used in RDTs and therefore would likely have many of the same storage requirements that trouble RDTs.

The major advantages of adapting PCR for POC diagnosis is that it is an extensively tested, proven technique (under laboratory conditions), which is capable of detecting extremely low level infections with high specificity and sensitivity. The drawback to using PCR at the POC is that it requires a large amount of infrastructure, including a thermocycler, a steady

TABLE 3  
Comparison of diagnostic characteristics that are relevant to the ability of a test to be useful at the point-of-care\*

Assay	Reference	Limit of detection	Time	Cost/test	Requirements	Tested in field?
Microscopy	19, 21	50 parasites/ $\mu$ L	20 minutes/slide	\$0.20†	Trained personnel, microscope, Giemsa stain	Yes
RDT	31	> 100 parasites/ $\mu$ L	20 minutes	\$0.45–\$1.40†	Cold chain for storage/transport of RDTs	Yes
Laboratory-based PCR	43	< 5 parasites/ $\mu$ L	1 hour	\$1.50–\$4 (reagents only)	Thermocycler, cold chain, power, reagent grade water	No
RT-PCR	65, 67	0.1–10 parasites/ $\mu$ L	1 hour	\$4–\$5 (reagents only)	DNA extraction, thermocycler, reagent water, power	No
PCR LDA	66, 68	0.3–10 parasites/ $\mu$ L		\$0.30 (detection only)	DNA extraction, PCR	No
PCR ELISA	70	< 30 parasites/ $\mu$ L	6 hours		DNA extraction, heat source, wellplate reader	Yes (Army hospital in Thailand)
LAMP	56, 57, 58, 60	0.2–5 parasites/ $\mu$ L	30 minutes–2 hours	\$0.40–\$0.70 (reagents only)	Heat source for amplification/DNA extraction,	No
NASBA	38, 62	0.01–0.1 parasites/ $\mu$ L	60 minutes	\$5–\$20 (reagents only)	Heat source for amplification, RNA extraction method, fluorescence measurement system	No
NALFIA	71	0.3–3 parasites/ $\mu$ L	1–1.5 hours		Self-contained test	Yes (Mbita, Kenya)

\*RDT = rapid diagnostic test; PCR = polymerase chain reaction; RT = reverse transcription; LDA = lactate dehydrogenase assay; ELISA = enzyme-linked immunosorbent assay; LAMP = loop-mediated isothermal amplification; NASBA = nucleic acid sequence–based amplification; NALFIA = nucleic acid lateral flow immunoassay.

†Costs listed for more established techniques (microscopy PCR and RDTs) reflect a more realistic cost to the end user including shipping, storage, and reagent costs. Costs listed for the techniques under development (RT-PCR, PCR LDA, PCR ELISA, LAMP, NASBA, and NALFIA) reflect only the cost of the materials required to perform the assay as given by the authors of the cited studies and likely underestimate the ultimate end cost to the user.

power supply, and reagent-grade water.<sup>79</sup> A variety of novel detection methods have been investigated, which when coupled with PCR, offer the potential for rapid (< 1 hour total time) accurate diagnosis and the potential to require less resources, less user intervention, and be more POC accessible than laboratory PCR. These detection methods are especially promising for future development because some of them may be coupled with isothermal amplification techniques to create totally self-contained tests.

## CONCLUSIONS

There is a growing interest in developing NATs for malaria diagnosis at the POC. The greatest advantage of NATs is their ability to detect extremely low level infections, which are often missed by microscopy and RDTs. The greatest barrier to NAT use in the past has been their relatively high cost and the amount of infrastructure required. These problems have been addressed in a variety of ways to decrease the cost, increase the ease of use, and maintain a high sensitivity and specificity and low limit of detection. The degree to which current and emerging malaria diagnostics have been able to meet the requirements of an effective POC diagnostic is summarized in Table 3. For the foreseeable future, NATs will likely remain more expensive for malaria diagnosis than RDTs, but may provide significant performance benefits for certain situations, which might outweigh their increased costs.

Isothermal amplification techniques, can be run in a short timeframe, require minimal infrastructure, and can detect extremely low levels of infection with high accuracy. The LAMP, in particular, is promising for further development as POC tool because it enables easy detection of the amplified product, is reasonably inexpensive, and it can be operated with minimal sample preparation. The greatest drawback for isothermal amplification is that, so far, it is relatively untested in realistic field conditions, which might significantly impact the performance of these tests.

The POC-focused detection strategies for more conventionally amplified targets generally focus on reducing the per test cost with methods that enable extremely high throughput, such as single-pot speciation. Although these techniques can be extremely sensitive, quick, and relatively inexpensive, many of them may be difficult to adapt into POC tools because of their reliance on extensive infrastructure. The NALFIA is the detection technique that may be best suited to the POC because it has already been tested under field conditions and is quick and simple to use. In addition, future work coupling NALFIA with an isothermal amplification system could result in a diagnostic that requires little infrastructure and maintains a low limit of detection compared with microscopy and RDTs.

Overall, the NATs being developed for detection of malaria at the POC have demonstrated that NATs can be easy to perform and maintain a low limit of detection and high sensitivity and specificity. The use of LAMP as a low-cost amplification method, coupled with low-cost detection such as turbidity or a scheme such as the PCR LDA, have the potential to create a NAT that is accessible in POC environments. The next major step in NAT development will be testing these techniques under realistic field conditions in

malaria-endemic countries. The integration of POC appropriate amplification technologies such as LAMP and NASBA with low-cost and easy to use detection systems such as NALFIA will be an important next step in realizing this goal.

Received November 2, 2011. Accepted for publication May 2, 2012.

Acknowledgments: We thank Veronica Leautaud for editorial assistance.

Financial support: This study was supported by a grant from the Bill & Melinda Gates Foundation through the Grand Challenges Explorations Initiative.

Authors' addresses: Michael S. Cordray, Department of Bioengineering, Rice University, Houston, TX, E-mail: mikec@rice.edu. Rebecca R. Richards-Kortum, Global Health Technologies, Rice University, Houston, TX, E-mails: rkortum@rice.edu or wichmann@rice.edu.

## REFERENCES

1. WHO, 2011. *Malaria*. Geneva: World Health Organization.
2. Cibulskis RE, Bell D, Christophel EM, Hii J, Delacollette C, Bakayita N, Aregawi MW, 2007. Estimating trends in the burden of malaria at country level. *Am J Trop Med Hyg* 77: 133–137.
3. Breman JG, Alilio MS, White NJ, 2007. Defining and defeating the intolerable burden of malaria. III. progress and perspectives. *Am J Trop Med Hyg* 77 (Suppl 6): vi–xi.
4. WHO, 2010. *World Malaria Report 2010*. Geneva: World Health Organization.
5. Uneke CJ, 2008. Impact of placental *Plasmodium falciparum* malaria on pregnancy and perinatal outcome in sub-Saharan Africa: Part III: placental malaria, maternal health, and public health. *Yale J Biol Med* 81: 1–7.
6. Matteelli A, Caligaris S, Castelli F, Carosi G, 1997. The placenta and malaria. *Ann Trop Med Parasitol* 91: 803–810.
7. WHO, 2011. *Universal Access to Malaria Diagnostic Testing*. Geneva: World Health Organization.
8. Das LK, Jambulingam P, Sadanandane C, 2008. Impact of community-based presumptive chloroquine treatment of fever cases on malaria morbidity and mortality in a tribal area in Orissa State, India. *Malar J* 7: 75.
9. Shillcutt S, Morel C, Goodman C, Coleman P, Bell D, Whitty CJ, Mills A, 2008. Cost-effectiveness of malaria diagnostic methods in sub-Saharan Africa in an era of combination therapy. *Bull World Health Organ* 86: 101–110.
10. Pfeiffer K, Some F, Muller O, Sie A, Kouyate B, Haefeli WE, Zougrana A, Gustafsson LL, Tomson G, Sauerborn R, 2008. Clinical diagnosis of malaria and the risk of chloroquine self-medication in rural health centres in Burkina Faso. *Trop Med Int Health* 13: 418–426.
11. Duraisingh MT, Refour P, 2005. Multiple drug resistance genes in malaria: from epistasis to epidemiology. *Mol Microbiol* 57: 874–877.
12. UNICEF, UNAIDS, Global Partnership to Roll Back Malaria, Population Services International, Management Services for Health, World Health Organization, Department of Essential Drugs and Medicines Policy, Médecins sans Frontières, 2004. *Sources and Prices of Selected Products for the Prevention, Diagnosis and Treatment of Malaria*. Geneva: World Health Organization.
13. Drakeley C, Reyburn H, 2009. Out with the old, in with the new: the utility of rapid diagnostic tests for malaria diagnosis in Africa. *Trans R Soc Trop Med Hyg* 103: 333–337.
14. Guerra CA, Snow RW, Hay SI, 2006. Mapping the global extent of malaria in 2005. *Trends Parasitol* 22: 353–358.
15. Coll-Black S, Bhushan A, Fritsch K, World Health Organization, Regional Office for the Western Pacific, 2006. *Integrating Poverty and Gender into Health Programmes: A Sourcebook for Health Professionals: Module on Malaria*. Manila: WHO Regional Office for the Western Pacific.
16. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI, 2005. The global distribution of clinical episodes of *Plasmodium falciparum* malaria. *Nature* 434: 214–217.



17. Peeling RW, Holmes KK, Mabey D, Ronald A, 2006. Rapid tests for sexually transmitted infections (STIs): the way forward. *Sex Transm Infect* 82: v1–v6.
18. Warhurst DC, Williams JE, 1996. ACP Broadsheet no 148. July 1996. Laboratory diagnosis of malaria. *J Clin Pathol* 49: 533.
19. Field JW, Shute PG, Sandosham AA, 1956. *The Microscopic Diagnosis of Human Malaria*. Kuala Lumpur: Government Press.
20. Kokoskin E, 2001. *The Malaria Manual for Today's Laboratory*. Montreal: McGill University Centre for Tropical Diseases.
21. Rodulfo H, De Donato M, Mora R, Gonzalez L, Contreras CE, 2007. Comparison of the diagnosis of malaria by microscopy, immunochromatography and PCR in endemic areas of Venezuela. *Braz J Med Biol Res* 40: 535–543.
22. Ngasala B, Mubi M, Warsame M, Petzold MG, Masele AY, Gustafsson LL, Tomson G, Premji Z, Bjorkman A, 2008. Impact of training in clinical and microscopy diagnosis of childhood malaria on antimalarial drug prescription and health outcome at primary health care level in Tanzania: a randomized controlled trial. *Malar J* 7: 199.
23. Coleman RE, Maneechai N, Rachaphaew N, Kumpitak C, Miller RS, Soyseng V, Thimasarn K, Sattabongkot J, 2002. Comparison of field and expert laboratory microscopy for active surveillance for asymptomatic *Plasmodium falciparum* and *Plasmodium vivax* in western Thailand. *Am J Trop Med Hyg* 67: 141–144.
24. Okell LC, Ghani AC, Lyons E, Drakeley CJ, 2009. Submicroscopic infection in *Plasmodium falciparum*-endemic populations: a systematic review and meta-analysis. *J Infect Dis* 200: 1509–1517.
25. Guthmann JP, Ruiz A, Priotto G, Kiguli J, Bonte L, Legros D, 2002. Validity, reliability and ease of use in the field of five rapid tests for the diagnosis of *Plasmodium falciparum* malaria in Uganda. *Trans R Soc Trop Med Hyg* 96: 254–257.
26. Bell D, Global Partnership to Roll Back Malaria, World Health Organization, Regional Office for the Western Pacific, 2004. *The Use of Malaria Rapid Diagnostic Tests*. Geneva: World Health Organization.
27. Lubell Y, Reyburn H, Mbakilwa H, Mwangi R, Chonya K, Whitty CJ, Mills A, 2007. The cost-effectiveness of parasitologic diagnosis for malaria-suspected patients in an era of combination therapy. *Am J Trop Med Hyg* 77: 128–132.
28. Ochola LB, Vounatsou P, Smith T, Mabaso ML, Newton C, 2006. The reliability of diagnostic techniques in the diagnosis and management of malaria in the absence of a gold standard. *Lancet Infect Dis* 6: 582–588.
29. Makler MT, Piper RC, Milhous WK, 1998. Lactate dehydrogenase and the diagnosis of malaria. *Parasitol Today* 14: 376–377.
30. Ratnawati, Hatta M, Smits HL, 2008. Point-of-care testing for malaria outbreak management. *Trans R Soc Trop Med Hyg* 102: 699–704.
31. Hopkins H, Bebell L, Kambale W, Dokomajilar C, Rosenthal PJ, Dorsey G, 2008. Rapid diagnostic tests for malaria at sites of varying transmission intensity in Uganda. *J Infect Dis* 197: 510–518.
32. Endeshaw T, Gebre T, Ngondi J, Graves PM, Shargie EB, Ejigsemahu Y, Ayele B, Yohannes G, Teferi T, Messele A, Zerihun M, Genet A, Mosher AW, Emerson PM, Richards FO, 2008. Evaluation of light microscopy and rapid diagnostic test for the detection of malaria under operational field conditions: a household survey in Ethiopia. *Malar J* 7: 118.
33. Bell D, Peeling RW, 2006. Evaluation of rapid diagnostic tests: malaria. *Nat Rev Microbiol* 4: S34–S38.
34. Wongsrichanalai C, Barcus MJ, Muth S, Sutamihardja A, Wernsdorfer WH, 2007. A review of malaria diagnostic tools: microscopy and rapid diagnostic test (RDT). *Am J Trop Med Hyg* 77: 119–127.
35. Murray CK, Bell D, Gasser RA, Wongsrichanalai C, 2003. Rapid diagnostic testing for malaria. *Trop Med Int Health* 8: 876–883.
36. World Health Organization, Regional Office for the Western Pacific, 2003. *Malaria Rapid Diagnosis: Making It Work. Informal Consultation on Field Trials and Quality Assurance on Malaria Rapid Diagnostic Tests*. Meeting Report January 20–23, 2003. Manila: WHO Regional Office for the Western Pacific.
37. WHO, 2009. *Malaria Rapid Diagnostic Test Performance*. Geneva: World Health Organization.
38. Houze S, Hubert V, Le Pessec G, Le Bras J, Clain J, 2011. Combined deletions of *pfhrp2* and *pfhrp3* genes result in *Plasmodium falciparum* malaria false-negative rapid diagnostic test. *J Clin Microbiol* 49: 2694–2696.
39. Gamboa D, Ho M-F, Bendezu J, Torres K, Chiodini PL, Barnwell JW, Incardona S, Perkins M, Bell D, McCarthy J, Cheng Q, 2010. A large proportion of *P. falciparum* isolates in the Amazon Region of Peru lack *pfhrp2* and *pfhrp3*: implications for malaria rapid diagnostic tests. *PLoS ONE* 5: e8091.
40. Lee N, Baker J, Andrews KT, Gattton ML, Bell D, Cheng Q, McCarthy J, 2006. Effect of sequence variation in *Plasmodium falciparum* histidine-rich protein 2 on binding of specific monoclonal antibodies: implications for rapid diagnostic tests for malaria. *J Clin Microbiol* 44: 2773–2778.
41. Jorgensen P, Chanthap L, Rebuena A, Tsuyuoka R, Bell D, 2006. Malaria rapid diagnostic tests in tropical climates: the need for a cool chain. *Am J Trop Med Hyg* 74: 750–754.
42. Hawkes M, Katsuva JP, Masumbuko CK, 2009. Use and limitations of malaria rapid diagnostic testing by community health workers in war-torn Democratic Republic of Congo. *Malar J* 8: 308.
43. Mayxay M, Pukrittayakamee S, Chotivanich K, Looareesuwan S, White NJ, 2001. Persistence of *Plasmodium falciparum* HRP-2 in successfully treated acute falciparum malaria. *Trans R Soc Trop Med Hyg* 95: 179–182.
44. Waitumbi JN, Gerlach J, Afonina I, Anyona SB, Koros JN, Siangla J, Ankoudinova I, Singhal M, Watts K, Polhemus ME, Vermeulen NM, Mahoney W, Steele M, Domingo GJ, 2011. Malaria prevalence defined by microscopy, antigen detection, DNA amplification and total nucleic acid amplification in a malaria-endemic region during the peak malaria transmission season. *Trop Med Int Health* 16: 786–793.
45. Mens P, Spieker N, Omar S, Heijnen M, Schallig H, Kager PA, 2007. Is molecular biology the best alternative for diagnosis of malaria to microscopy? A comparison between microscopy, antigen detection and molecular tests in rural Kenya and urban Tanzania. *Trop Med Int Health* 12: 238–244.
46. Tahar R, Basco LK, 1997. Detection of *Plasmodium ovale* malaria parasites by species-specific 18S rRNA gene amplification. *Mol Cell Probes* 11: 389–395.
47. Das A, Holloway B, Collins WE, Shama VP, Ghosh SK, Sinha S, Hasnain SE, Talwar GP, Lal AA, 1995. Species-specific 18S rRNA gene amplification for the detection of *P. falciparum* and *P. vivax* malaria parasites. *Mol Cell Probes* 9: 161–165.
48. Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalama FK, Takala SL, Taylor TE, Plowe CV, 2006. Return of chloroquine antimalarial efficacy in Malawi. *N Engl J Med* 355: 1959–1966.
49. Coleman PG, Morel C, Shillcutt S, Goodman C, Mills AJ, 2004. A threshold analysis of the cost-effectiveness of artemisinin-based combination therapies in sub-Saharan Africa. *Am J Trop Med Hyg* 71: 196–204.
50. Snounou G, Viriyakosol S, Jarra W, Thaithong S, Brown KN, 1993. Identification of the four human malaria parasite species in field samples by the polymerase chain reaction and detection of a high prevalence of mixed infections. *Mol Biochem Parasitol* 58: 283–292.
51. Srinivasan S, Moody AH, Chiodini PL, 2000. Comparison of blood-film microscopy, the OptiMAL dipstick, rhodamine-123 fluorescence staining and PCR, for monitoring antimalarial treatment. *Ann Trop Med Parasitol* 94: 227–232.
52. McCutchan TF, 1986. The ribosomal genes of *Plasmodium*. *Int Rev Cytol* 99: 295–309.
53. Hänscheid T, Grobusch MP, 2002. How useful is PCR in the diagnosis of malaria? *Trends Parasitol* 18: 395–398.
54. Johnston SP, Pieniazek NJ, Xayavong MV, Slemenda SB, Wilkins PP, da Silva AJ, 2006. PCR as a confirmatory technique for laboratory diagnosis of malaria. *J Clin Microbiol* 44: 1087–1089.
55. Ndao M, Bandyayera E, Kokoskin E, Gyorkos TW, MacLean JD, Ward BJ, 2004. Comparison of blood smear, antigen detection, and nested-PCR methods for screening refugees from regions where malaria is endemic after a malaria outbreak in Quebec, Canada. *J Clin Microbiol* 42: 2694–2700.
56. Khairnar K, Martin D, Lau R, Ralevski F, Pillai DR, 2009. Multiplex real-time quantitative PCR, microscopy and rapid

- diagnostic immuno-chromatographic tests for the detection of *Plasmodium* spp: performance, limit of detection analysis and quality assurance. *Malar J* 8: 284.
57. Perandin F, Manca N, Calderaro A, Piccolo G, Galati L, Ricci L, Medici MC, Arcangeletti MC, Snounou G, Dettori G, Chezzi C, 2004. Development of a real-time PCR assay for detection of *Plasmodium falciparum*, *Plasmodium vivax*, and *Plasmodium ovale* for routine clinical diagnosis. *J Clin Microbiol* 42: 1214–1219.
  58. New England Biolabs, 2011. *Taq PCR Kit*.
  59. QIAGEN, 2011. *QuantiTect SYBR Green PCR Kits*.
  60. QIAGEN, 2011. *QuantiTect Multiplex PCR Kits*.
  61. World Scientific, 2011. *Lambda PCR Kit*.
  62. Bell D, Wongsrichanalai C, Barnwell JW, 2006. Ensuring quality and access for malaria diagnosis: how can it be achieved? *Nat Rev Microbiol* 4: S7–S20.
  63. Breman JG, Alilio MS, Mills A, 2004. Conquering the intolerable burden of malaria: what's new, what's needed: a summary. *Am J Trop Med Hyg* 71: 1–15.
  64. Vincent M, Xu Y, Kong H, 2004. Helicase-dependent isothermal DNA amplification. *EMBO Rep* 5: 795–800.
  65. Lizardi PM, Huang X, Zhu Z, Bray-Ward P, Thomas DC, Ward DC, 1998. Mutation detection and single-molecule counting using isothermal rolling-circle amplification. *Nat Genet* 19: 225–232.
  66. Van Ness J, Van Ness LK, Galas DJ, 2003. Isothermal reactions for the amplification of oligonucleotides. *Proc Natl Acad Sci USA* 100: 4504–4509.
  67. Notomi T, Okayama H, Masubuchi H, Yonekawa T, Watanabe K, Amino N, Hase T, 2000. Loop-mediated isothermal amplification of DNA. *Nucleic Acids Res* 28: E63.
  68. Mori Y, Nagamine K, Tomita N, Notomi T, 2001. Detection of loop-mediated isothermal amplification reaction by turbidity derived from magnesium pyrophosphate formation. *Biochem Biophys Res Commun* 289: 150–154.
  69. Tomita N, Mori Y, Kanda H, Notomi T, 2008. Loop-mediated isothermal amplification (LAMP) of gene sequences and simple visual detection of products. *Nat Protoc* 3: 877–882.
  70. Poon LL, Wong BW, Ma EH, Chan KH, Chow LM, Abeyewickreme W, Tangpukdee N, Yuen KY, Guan Y, Looareesuwan S, Peiris JS, 2006. Sensitive and inexpensive molecular test for falciparum malaria: detecting *Plasmodium falciparum* DNA directly from heat-treated blood by loop-mediated isothermal amplification. *Clin Chem* 52: 303–306.
  71. Han ET, Watanabe R, Sattabongkot J, Khuntirat B, Sirichaisinthop J, Iriko H, Jin L, Takeo S, Tsuboi T, 2007. Detection of four *Plasmodium* species by genus- and species-specific loop-mediated isothermal amplification for clinical diagnosis. *J Clin Microbiol* 45: 2521–2528.
  72. Paris DH, Imwong M, Faiz AM, Hasan M, Yunus EB, Silamut K, Lee SJ, Day NP, Dondorp AM, 2007. Loop-mediated isothermal PCR (LAMP) for the diagnosis of falciparum malaria. *Am J Trop Med Hyg* 77: 972–976.
  73. LaBarre P, Gerlach J, Wilmoth J, Beddoe A, Singleton J, Weigl B, 2010. *Non-Instrumented Nucleic Acid Amplification (NINA): Instrument-Free Molecular Malaria Diagnostics for Low-Resource Settings*. Engineering in Medicine and Biology Society (EMBC), 2010 Annual International Conference of the IEEE, 1097–1099.
  74. Polley SD, Mori Y, Watson J, Perkins MD, Gonzalez IJ, Notomi T, Chiodini PL, Sutherland CJ, 2010. Mitochondrial DNA targets increase sensitivity of malaria detection using loop-mediated isothermal amplification. *J Clin Microbiol* 48: 2866–2871.
  75. Compton J, 1991. Nucleic acid sequence-based amplification. *Nature* 350: 91–92.
  76. Mens PF, Schoone GJ, Kager PA, Schallig H, 2006. Detection and identification of human *Plasmodium* species with real-time quantitative nucleic acid sequence-based amplification. *Malar J* 5: 80.
  77. Marangi M, Di Tullio R, Mens P, Martinelli D, Fazio V, Angarano G, Schallig H, Giangaspero A, Scotto G, 2009. Prevalence of *Plasmodium* spp. in malaria asymptomatic African migrants assessed by nucleic acid sequence based amplification. *Malar J* 8: 12.
  78. Landry ML, Garner R, Ferguson D, 2003. Comparison of the NucliSens basic kit (nucleic acid sequence-based amplification) and the Argene Biosoft Enterovirus Consensus reverse transcription-PCR assays for rapid detection of enterovirus RNA in clinical specimens. *J Clin Microbiol* 41: 5006–5010.
  79. Swan H, Sloan L, Muyombwe A, Chavalitshekwinkoon-Petmitr P, Krudsood S, Leowattana W, Wilairatana P, Looareesuwan S, Rosenblatt JON, 2005. Evaluation of a real-time polymerase chain reaction assay for the diagnosis of malaria in patients from Thailand. *Am J Trop Med Hyg* 73: 850–854.
  80. McNamara DT, Thomson JM, Kasehagen LJ, Zimmerman PA, 2004. Development of a multiplex PCR-ligase detection reaction assay for diagnosis of infection by the four parasite species causing malaria in humans. *J Clin Microbiol* 42: 2403–2410.
  81. Lee M-A, Tan C-H, Aw L-T, Tang C-S, Singh M, Lee S-H, Chia H-P, Yap EP, 2002. Real-time fluorescence-based PCR for detection of malaria parasites. *J Clin Microbiol* 40: 4343–4345.
  82. McNamara DT, Kasehagen LJ, Grimberg BT, Cole-Tobian J, Collins WE, Zimmerman PA, 2006. Diagnosing infection levels of four human malaria parasite species by a polymerase chain reaction/ligase detection reaction fluorescent microsphere-based assay. *Am J Trop Med Hyg* 74: 413–421.
  83. Mori Y, Hirano T, Notomi T, 2006. Sequence specific visual detection of LAMP reactions by addition of cationic polymers. *BMC Biotechnol* 6: 3.
  84. Laoboonchai A, Kawamoto F, Thanosingha N, Kojima S, Scott Miller RR, Kain KC, Wongsrichanalai C, 2001. PCR-based ELISA technique for malaria diagnosis of specimens from Thailand. *Trop Med Int Health* 6: 458–462.
  85. Mens PF, van Amerongen A, Sawa P, Kager PA, Schallig HD, 2008. Molecular diagnosis of malaria in the field: development of a novel 1-step nucleic acid lateral flow immunoassay for the detection of all 4 human *Plasmodium* spp. and its evaluation in Mbita, Kenya. *Diagn Microbiol Infect Dis* 61: 421–427.